We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > P2Y12

News List

Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19 drugs.com
January 18, 2022
The addition of a P2Y12 inhibitor to anticoagulant therapy does not improve organ support-free days among non-critically ill patients hospitalized for COVID-19...
Daiichi Sankyo Presents Positive Results from LIXIANA Study americanpharmaceuticalreview
September 05, 2019
Daiichi Sankyo announced results from ENTRUST-AF PCI, the first large randomized study to evaluate the efficacy and safety of once-daily edoxaban (known by the brand name LIXIANA®▼) plus a P2Y12 inhibitor...
Idorsia's selatogrel hits goals in phase 2 cardiovascular trials fiercebiotech
December 25, 2018
Idorsia's P2Y12 receptor antagonist selatogrel has significantly inhibited platelet aggregation in two phase 2 trials. The primary endpoint successes in patients with ....